Sanofi
Nadège Bailleul inspects a set of 12 small clear vials on a steel rack next to a fume hood in a darkened room

Nadège Bailleul, Mirage operator, Val de Reuil, France

Nadège Bailleul, Mirage operator, Val de Reuil, France

Second Quarter 2025

Second quarter 2025 results will be reviewed by management during a live audio webcast with the financial community.


Our Latest Stories

Illustration depicting genomic medicine in 3D

Our Science

July 24, 2025

Genomic Medicine Unit: Overcoming Gene Therapy’s Greatest Challenges

United by Purpose

Each of us plays a unique role in bringing our purpose to life.

About Us

Who We Are

We are an R&D driven,
AI-powered biopharma company committed to improving people’s lives and creating compelling growth.

Our Pipeline

5

Therapeutic areas

86

Compounds in clinical development

24

Clinical trials in phase 3

Pursue Progress. Discover Extraordinary. 

Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.

Our Latest Press Releases


July 31, 2025
Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range

July 30, 2025
Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma

July 25, 2025
Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma

July 22, 2025
Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline